​Turning science into executable strategy.
Orchid is a specialized advisory firm for biopharma, working closely with founders, executives, and investors to navigate critical development and fundraising decisions. With deep experience across development, fundraising, and business development, the firm helps teams sharpen their narratives, map realistic paths to value creation, and engage the right investors and partners with confidence. Orchid’s mission is to help high-potential biotech companies move faster, communicate more clearly, and position themselves for meaningful inflection points.
Services
Orchid works with founders, executives, and investors across the life sciences ecosystem. The firm provides integrated strategic advisory support across development, fundraising, and partnering activities.
About Us
Why Orchid
The most important decisions in biotech are made long before a data readout, a financing, or a partnership discussion. They are made in how a company frames its science, selects its path to proof-of-concept, and communicates its vision. Orchid exists to guide companies through these decisions with clarity and confidence.
​
​Deep involvement in the details
Orchid takes a hands-on approach to understanding the underlying science, datasets, and assumptions that drive development. This allows the firm to produce strategies that are both scientifically credible and operationally realistic.
Operator perspective
Having led biotech programs through development, fundraising, and M&A, Orchid understands the practical constraints founders face: budgets, timelines, regulatory requirements, and investor psychology. This perspective informs strategies designed for real execution.
Investor fluency
Orchid works at the intersection of science and capital. The firm has deep experience shaping narratives, preparing materials, and guiding teams through investor diligence processes, ensuring that the story, the data, and the roadmap align.
​
Orchid is the right partner for founders and executives who want clarity, rigor, and strategic guidance that recognizes the realities of biotech development.
​
